Pharma Data Procurement Guide | GDPR Compliance Pharma & Internal RWE Buy-In for Claims Data Vendor Engagement

Here’s a scenario that will feel uncomfortably familiar to anyone who has tried to initiate a real-world data programme inside a large pharmaceutical organisation. You’ve done the work. You’ve identified the evidence gap, evaluated your options, found a data source that fits your use case, and got verbal support from your function head. You have, in principle, a budget. And then… it stalls.

Legal needs a compliance briefing nobody on your team knows how to produce. IT has raised a security assessment query that the vendor can’t seem to answer in the format required. Finance is asking where in the budget this should sit — it’s not software, it’s not consulting, it’s not a clinical trial, and nobody has processed this type of commitment before. Procurement wants three quotes for a competitive tender, but doesn’t know what criteria to use to evaluate them.

Six months later, the submission window has narrowed. The competitor launched two quarters ago. The payer negotiation proceeded without the comparative effectiveness evidence you were trying to generate. And the data engagement is still in legal review.

This is the last-mile problem of pharma real-world evidence strategy — and it’s more common than anyone in the industry talks about publicly. Most RWE content focuses on what real-world data can do. This post focuses on something more immediately useful: how to get your organisation to agree to buy it. That distinction is the whole point.

Before you engage a single internal stakeholder, read this. It will save you months.

Who Is Actually in the Room: Mapping Your Internal Approval Landscape

The first mistake most RWE and market access teams make is treating the internal approval process as a single conversation. It isn’t. It’s a series of parallel conversations with different functions, each of which has completely different concerns, completely different documentation requirements, and — critically — no particular incentive to move quickly.

Understanding what each function actually needs before you approach them is the difference between a process that takes eight weeks and one that takes eight months.

Legal and Compliance are risk managers, not obstructionists. Their primary concerns are GDPR compliance for Continental European health data, HIPAA compliance if US data is involved, data processing agreement requirements, liability exposure from data misuse, and the intellectual property implications of third-party data licensing. They will approve the engagement — but only when specific questions have been answered. The problem is that most RWE teams don’t know what those questions are until legal raises them, by which point the review has already stalled. Knowing the questions in advance changes the timeline dramatically.

IT and Data Engineering receive RWD vendor engagement requests constantly — and their default response to inadequate technical documentation is a pause, not a refusal. What they need is a clear specification of the data access model (API, secure environment, or direct delivery), cloud architecture and data residency documentation, and an information security assessment pack. When that documentation arrives with the initial request, rather than six weeks into a review cycle, the IT assessment compresses from months to weeks.

Finance and Procurement need a business case in financial language. Not evidence quality language. Not scientific credibility language. Financial language: quantified value, identified risk, cost-benefit framing, and a clear budget category for a type of expenditure that most finance teams have never processed before. The typical RWE team’s justification — “we’ll generate better evidence” — doesn’t translate into the terms procurement requires.

Medical and Regulatory Affairs are generally allies rather than blockers — but only if they’re engaged early enough to contribute to vendor evaluation rather than being asked to validate decisions that have already been made. A retrospective concern from regulatory affairs about a data source’s fitness for a regulatory submission is far more damaging than the same concern raised during the evaluation process.

Map these stakeholders before you approach any of them. Understand what each one needs. Then prepare the documentation before you walk into the room.

What Your Legal Team Needs to Know About Claims Data

Legal teams that are familiar with clinical trial contracts and software licensing agreements often approach a health data licensing engagement without the specific framework needed to evaluate it efficiently. The result is a cautious, conservative review that applies more restrictive requirements than the data actually warrants — simply because the internal expertise to distinguish genuinely anonymised data from inadequately de-identified data doesn’t exist in most pharma legal functions.

Your job, as the person driving the engagement, is to close that knowledge gap before the formal review begins. Here’s what to prepare.

The anonymisation distinction under GDPR Article 9

This is the most important concept for your legal team to understand, and the one that most commonly generates unnecessary delay. Under GDPR Article 9, health data is classified as special category data and subject to strict processing restrictions. But genuinely anonymised data — data that has been processed in such a way that re-identification of individuals is no longer reasonably possible — falls outside GDPR’s scope entirely.

Pseudonymised data, by contrast, is still personal data under GDPR. It has been processed to replace direct identifiers with codes, but re-identification remains possible with access to a key. The two categories require entirely different legal bases, different contractual protections, and different compliance approaches. Many legal teams apply pseudonymisation-level scrutiny to data that is genuinely anonymised — creating compliance overhead that the data doesn’t require.

Equip your legal team with a clear explanation of which category the proposed data falls into, and how the vendor’s anonymisation methodology has been validated. The European Data Protection Board’s guidance on anonymisation standards is the authoritative reference. Know it. Brief legal on it before the review begins.

For a more detailed breakdown of what aggregated and anonymised health insurance data actually is — and how it differs from patient-level data — the MEDDDICAL overview of aggregated and synthetic insurance data covers the distinctions that matter most for the GDPR compliance conversation.

Data Processing Agreements: what to look for

Every GDPR-compliant health data engagement requires a Data Processing Agreement. What slows legal review is not the existence of DPA requirements — it’s the fact that the vendor’s standard DPA often doesn’t address the specific concerns the internal legal team needs resolved. Common gaps include clarity on data sub-processing arrangements, audit rights, breach notification timelines, and the basis for any cross-border data transfers.

Request the vendor’s standard DPA early — ideally before formal legal engagement begins — and review it against your organisation’s standard DPA requirements. Identify the gaps before legal does. Arriving at legal review with a redline DPA already prepared is a materially different conversation from arriving with a vendor’s standard template and no prior analysis.

Cross-border data transfers in Pan-European analyses

For analyses covering multiple Continental European markets, the cross-border data transfer question is almost certain to arise — and it almost always arises later in the review process than it should. Under GDPR, transfers of personal data outside the EEA require an appropriate transfer mechanism: Standard Contractual Clauses, an adequacy decision, or binding corporate rules. For genuinely anonymised data, the transfer restriction doesn’t apply — which is another reason the anonymisation distinction matters.

Anticipate this question. If the data is genuinely anonymised, document why the transfer restriction doesn’t apply. If it isn’t, identify the transfer mechanism the vendor relies on and verify that it’s current and appropriate. The EDPB guidance on international data transfers is the reference your legal team will use. Know it before they do.

Intellectual property and licensing rights

What a data licensing agreement actually grants you matters more than most RWE teams appreciate at the point of signature. Usage rights, publication rights, sublicensing restrictions, exclusivity terms, and ownership of analytical outputs generated from licensed data all need to be clearly specified — and they’re all negotiable. The question of who owns the analytical outputs is particularly important if those outputs will be used in regulatory submissions or publications: the answer isn’t always the licensee.

Auto-renewal clauses and scope limitations in multi-year agreements also deserve specific legal attention. A two-year licensing commitment with an automatic renewal clause and a narrow scope definition can create commercial and operational constraints that weren’t anticipated at signature.

If the engagement involves US data alongside European data, your legal team also needs to understand HIPAA’s Expert Determination and Safe Harbor de-identification standards — and specifically which standard the vendor has applied. Business Associate Agreement requirements for US health data are distinct from GDPR DPA requirements and need to be addressed in parallel rather than sequentially.

What Your IT Team Needs to Know About RWD Vendor Engagement

The single most common cause of IT-related approval delays is simple: IT received a data vendor engagement request without the documentation needed to complete a standard information security assessment. Their response — universally — is to pause the review until the documentation arrives. If that documentation arrives six weeks into the review rather than on day one, the review timeline extends by exactly those six weeks.

Here’s what to request from the vendor — and provide to IT — before internal engagement begins.

Data access model specification

The three primary data access models — API-based access, secure data environment access, and direct data delivery — have materially different IT infrastructure requirements. An API integration requires compatibility assessment with existing analytical platforms, API documentation, and potentially development resource. A secure data environment requires VPN or browser-based access configuration and agreement on what can and cannot be exported. Direct delivery requires a secure transfer protocol, storage architecture decisions, and data pipeline engineering.

IT needs to know which model is proposed and what it requires before they can begin their assessment. Don’t leave them to discover this during the review. The MEDDDICAL overview of real-world and synthetic healthcare data for pharma and MedTech covers the different data access approaches and what each implies for technical infrastructure.

Cloud architecture and GDPR data residency

GDPR imposes specific requirements on where data is stored and processed — and for Continental European health data, the data residency question is one that IT will raise without fail. The vendor’s cloud architecture documentation needs to specify where data is stored, where processing occurs, and whether any sub-processors are involved in storage or processing outside the EEA.

This sounds straightforward. In practice it often isn’t — particularly for vendors whose analytical platforms are hosted on US-based cloud infrastructure with EEA data regions. The documentation needs to address not just where data resides at rest, but where it moves during processing. Request this documentation proactively. IT will ask for it. Better that you provide it before they ask.

Information security assessment pack

Most vendors serving regulated industries maintain a standard information security assessment pack that addresses the questions enterprise IT security teams typically raise: ISO 27001 certification or equivalent, penetration testing documentation, access control architecture, encryption standards, incident response procedures, and business continuity arrangements. Request this pack explicitly — and provide it to IT simultaneously with the initial engagement notification. An IT security review that begins with a complete documentation set is a fundamentally different process from one that begins with a request for documentation.

Integration architecture and engineering resource

The gap between licensing data and having that data available for analysis in your existing infrastructure is almost always larger than the RWE team anticipates. Data engineering resource is required to build and maintain the connection between the licensed data and the analytical environment — and that resource is often not budgeted in the initial engagement request. Identify the integration requirements early, quantify the engineering resource needed, and include it in the total cost of ownership that finance will review.

How to Build the Business Case for Finance and Procurement

The business case for real-world data investment is consistently one of the weakest documents produced by RWE and market access teams — not because the value isn’t real, but because it’s expressed in terms that finance teams cannot act on.

“Better evidence for payer submissions” is not a business case. “Access to claims data covering key Continental European markets” is not a financial justification. Finance needs numbers. Specifically: the cost of the problem you’re solving, the value of the solution, and a credible basis for both estimates.

Quantifying the cost of not having the data

The most persuasive business case for RWD investment is not a benefits case — it’s a cost-of-failure case. Consider the quantifiable consequences of the specific evidence gap you’re addressing:

Delayed market access: For a specialty pharma asset, each month of delayed reimbursement approval carries a quantifiable opportunity cost in foregone net sales. If your claims data engagement supports a payer submission that accelerates approval by even two months, the value of that acceleration — expressed as foregone revenue recovered — is almost certainly larger than the cost of the data.
Failed or resubmitted HTA submissions: The cost of an inadequate evidence package for an HTA submission — in additional study design, data collection, regulatory consultation, and delayed reimbursement — is substantial. The cost of doing it right the first time is, by comparison, modest. The MEDDDICAL overview of HEOR simulation and cost modelling with aggregated insurance data addresses the payer evidence value case in detail.
Market sizing errors: Overestimating or underestimating the addressable patient population has direct commercial consequences — manufacturing overcapacity, undersized sales forces, misallocated launch investment. Claims-based market sizing reduces the probability of these errors materially. The cost of a sizing error is quantifiable. The cost of the data that prevents it is also quantifiable. The comparison is usually compelling.
Missed competitive intelligence windows: The commercial impact of detecting a competitor’s prescribing pattern shift three months earlier — in brand defence investment, key account prioritisation, or portfolio strategy — is real and estimable. The value of timely, claims-based competitive intelligence can be framed in financial terms that a commercial finance team will understand. The MEDDDICAL post on pharma and MedTech market intelligence provides the framework for this conversation.

Structuring the business case document

A finance and procurement-ready business case for a real-world data engagement should contain, at minimum:

Executive summary — one page, in commercial language, stating the evidence question, the proposed solution, the total cost, and the quantified expected return. If senior leadership reads only this page, they should be able to make a decision.
Use case specification — what specific analytical questions the data will answer and how those answers inform specific named business decisions. Not “better evidence.” Not “improved understanding.” Specific decisions: a payer negotiation submission, a launch sizing exercise, a Phase IV design.
Vendor evaluation summary — how the selected partner was evaluated against the relevant alternatives and why it represents the best fit for the specified use cases. This is also what satisfies procurement’s competitive process requirements — more on this below.
Total cost of ownership — licensing fees, implementation and integration costs, ongoing engineering resource, renewal terms, and any variable costs. Finance will find costs you didn’t include. Find them first.
Risk assessment — GDPR and HIPAA compliance verification, vendor financial stability, data quality validation approach, and contractual protections against data quality failure.
ROI framework — quantified value estimates for each use case, timeline to value realisation, and success metrics that can be measured after the engagement completes.

The budget categorisation problem

Here’s something that stops more data engagements than it should: nobody knows where to put it in the budget. It’s not software. It’s not consulting. It’s not a clinical trial. It’s not a market research subscription. Finance will raise this question — and if you don’t have an answer prepared, it creates a delay that has nothing to do with the merits of the engagement.

Work with finance proactively — before the formal approval process begins — to establish how this type of expenditure should be categorised in your organisation. Once the category is established for the first engagement, every subsequent one is faster.

Managing competitive procurement requirements

When the contract value exceeds your organisation’s mandatory competitive tender threshold — which it often will for a multi-year claims data licensing agreement — procurement will require a competitive process. The problem is that standard procurement vendor evaluation frameworks are designed for software or services, not for real-world data capabilities. Applied naively to a data vendor evaluation, they select for the wrong things.

The solution is to prepare an evaluation framework that satisfies procurement’s competitive process requirements while using criteria that are genuinely appropriate for assessing real-world data capability: geographic coverage across target markets, ICD-10 coding and ATC classification completeness, longitudinal tracking methodology, GDPR compliance documentation, anonymisation validation, analytical query infrastructure, and time-to-insight. A rigorous, documented vendor evaluation framework that addresses these dimensions simultaneously gives procurement the competitive process they need and you the evaluation outcome that reflects actual data quality.

The Vendor Evaluation Framework That Satisfies All Stakeholders

Here’s the insight that compresses the approval timeline more than anything else: a rigorous vendor evaluation process, conducted before internal stakeholder engagement begins, can transform the internal approval from a sequential series of information requests and reviews into a parallel assessment that completes in weeks rather than months.

The reason is simple. Most approval delays are caused by internal stakeholders discovering documentation gaps during their review. Legal asks for the DPA. IT asks for the security pack. Finance asks for the vendor’s financial stability evidence. Each request triggers a vendor response cycle, which triggers a review cycle, which adds weeks to the timeline. If all that documentation exists before the review begins — because you gathered it during vendor evaluation — the parallel review can proceed without interruption.

The documentation you should gather during vendor evaluation, and provide to each function simultaneously when you initiate internal review:

For Legal: Data processing agreement (or standard template), anonymisation methodology documentation with validation evidence, GDPR compliance statement (Article 9 specifically), HIPAA certification where relevant, cross-border transfer mechanism documentation, and intellectual property and licensing terms.
For IT: Information security assessment pack (ISO 27001 or equivalent), cloud architecture and data residency documentation, API technical documentation, data access model specification, and sub-processor list.
For Finance and Procurement: Detailed pricing breakdown, contract terms summary including renewal and exit provisions, vendor financial stability evidence (annual reports, audited accounts), and — where available — reference customer list.
For Medical and Regulatory Affairs: Validation study results or published validation methodology, regulatory acceptance track record for the intended use case, published studies using the data source, and therapeutic area coverage specifics.

Understanding which combination of coverage, analytical capabilities, compliance documentation, and domain expertise actually fits your specific use cases requires deep familiarity with the Pan-European data landscape — familiarity that most organisations don’t have internally. This is where expert advisory support becomes genuinely valuable: not just in identifying the right data source, but in knowing what documentation to request and how to present it to each internal stakeholder in a way that addresses their specific concerns efficiently.

Before you’re at this stage, it’s worth working through how you arrived at a vendor shortlist in the first place. The criteria for evaluating pharma data providers are covered in MEDDDICAL’s post on aggregated and synthetic insurance data — a useful starting point if you’re still at the evaluation stage.

Common Internal Approval Blockers — and How to Address Them

Even with good preparation, blockers arise. Here are the most common ones, and the specific strategies that resolve them.

“Legal review will take months.”

Root cause: legal was engaged after vendor selection, has no prior context for health data licensing under GDPR, and is working through compliance questions for the first time without a prepared documentation set. Solution: engage legal at the start of the vendor evaluation — not the end. Brief them on the type of data, the relevant GDPR considerations, and what the engagement will require, before a vendor is selected. Establish a dedicated legal point of contact for the programme. Arrive at formal legal review with a complete documentation pack and a pre-prepared DPA redline. A legal team that begins a review with all required documentation in hand is a materially different partner than one that begins by generating an information request list.

“IT security assessment has been open for three months.”

Root cause: IT received the engagement notification without a technical documentation pack, raised a documentation request, and is waiting for a vendor response that is taking longer than either side anticipated. Solution: as described above — request the vendor’s security documentation pack before IT engagement begins and provide it simultaneously with the initial request. If the assessment is already stalled, escalate the documentation request directly with the vendor and provide IT with a clear timeline for when each outstanding document will arrive. An IT assessment with a documentation gap has one lever: filling the gap as fast as possible.

“Finance can’t categorise this in the budget.”

Root cause: the organisation has no established budget category for commercial health data licensing. The expenditure doesn’t fit software, consulting, or clinical costs — and finance’s response to an uncategorisable expenditure is delay, not refusal. Solution: get ahead of this by working with finance before the formal approval request. Propose a categorisation — data licensing or research data infrastructure are common framings — and get informal agreement before the formal business case is submitted. The categorisation conversation is much faster when it happens informally before the review than when it’s raised as a blocker during it.

“Procurement requires a competitive tender.”

Root cause: the contract value exceeds the competitive tender threshold, and procurement’s standard evaluation framework is not calibrated for real-world data capability assessment. Solution: offer to design the evaluation framework. A procurement team that lacks domain expertise in health data will typically accept a framework proposed by the function driving the engagement — provided it demonstrates genuine competitive evaluation. Design it so that the evaluation criteria reflect actual RWD capability: coverage, methodology, compliance documentation, analytical infrastructure. Procurement gets a competitive process. You get a process that identifies the right partner.

“A senior stakeholder doesn’t understand why this is different from existing data subscriptions.”

Root cause: the distinction between a claims data engagement for regulatory-grade evidence generation and a commercial market data subscription has not been communicated clearly — and the default assumption is that they’re broadly similar in terms of what approval they require. Solution: prepare a one-page explainer that positions the engagement in the context of a specific strategic decision — a payer negotiation, a regulatory submission, a launch sizing exercise — rather than as a generic data purchase. Make the evidence question concrete. Make the business consequences of not having the evidence concrete. The comparison with existing subscriptions dissolves when the specific strategic stakes are clear.

A Realistic Timeline for Internal Approval

Setting accurate expectations for the internal approval timeline is itself a risk management exercise. Teams that expect four weeks and experience twelve have very different conversations with leadership than teams that anticipated twelve and delivered in ten.

Here is a realistic timeline for a well-prepared internal approval process for a Pan-European claims data engagement:

Weeks 1–2: Stakeholder mapping and documentation preparation. Identify all required approvers and their specific documentation requirements. Gather vendor compliance, security, and commercial documentation. Prepare stakeholder-specific briefing materials. Do not initiate formal review until this is complete.

Weeks 3–4: Parallel stakeholder engagement. Brief legal, IT, finance, and medical affairs simultaneously — not sequentially. The single most effective compression lever in the entire process is parallelising reviews that are typically run sequentially. Each sequential review adds its full duration to the timeline. Parallel reviews add only the longest review’s duration.

Weeks 5–8: Review and response cycle. Manage incoming queries from each function. Provide supplementary documentation as required. Identify blockers early and escalate through appropriate channels — waiting for blockers to resolve themselves is the most common cause of approval timeline extension.

Weeks 9–12: Contract negotiation and finalisation. Legal review of contract terms, procurement process completion, final budget approval. For complex multi-year engagements or engagements involving novel data types, allow for the upper end of this range.

A well-prepared internal approval process takes eight to twelve weeks. An unprepared one takes six to twelve months. The difference is almost entirely determined by whether stakeholder concerns were anticipated and documented before engagement began — not by the complexity of the data engagement itself.

Getting Started: What to Do Before You Approach Any Stakeholder

If you’ve read this far and you’re thinking “I should have started this process two months ago” — that’s the right reaction. The internal approval process for a pharma real-world data engagement is almost always longer than it looks from the outside. Starting it earlier than feels necessary is the single most reliable way to prevent it from becoming a programme-threatening delay.

Here’s where to start, in order:

Define the evidence question and the specific business decision it informs — before engaging any internal stakeholder. Not “we need claims data.” A specific question: “What is the treated prevalence of condition X across five Continental European markets, stratified by line of therapy, to size the Phase IV cohort?” The specificity of the evidence question determines the specificity of the data requirement, which determines what kind of vendor engagement is needed, which determines what internal approvals are required.
Map all required approvers and understand what each one needs to see before they can approve. Don’t discover approval requirements during the review process.
Prepare stakeholder-specific briefing documents before initiating any formal engagement. Legal briefing. IT technical specification. Finance business case. Medical affairs regulatory acceptability summary. One set of documents, four different framings of the same engagement.
Engage expert advisory support early. The Pan-European real-world data landscape is complex enough that most organisations don’t have the internal expertise to simultaneously evaluate data sources, design compliance documentation, and prepare the internal business case. Expert advisors who understand both the evidence requirements and the vendor landscape can accelerate this process materially — and help you avoid the vendor selection mistakes that generate additional approval friction after the fact. The MEDDDICAL RWE strategy and analytics service exists for exactly this purpose.
Start the internal process earlier than feels necessary. It will take longer than you expect. It always does. The only reliable hedge is starting early enough that the timeline can absorb the unexpected without affecting the programme.

Once the internal approval is complete and the engagement is initiated, the next question is what analysis-ready real-world evidence actually looks like in practice — and how to structure the programme to generate outputs that are fit for their intended purpose. MEDDDICAL’s post on analysis-ready real-world evidence and healthcare data for pharma covers this directly.

If you’re navigating an internal approval process right now — or anticipating one — the most useful conversation you can have is with an advisor who has been through it many times and understands where the friction points are before they become blocking issues. Contact MEDDDICAL to discuss your specific evidence requirements and how we can help you navigate the internal process from requirements definition through to engagement initiation.